Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kristie Fields"'
Autor:
Michael Simon, Lawrence Flaherty, Lawrence G. Lum, Archana Thakur, Abhinav Deol, Kristie Fields, Dana Schalk, Zaid Al-Kadhimi, Vidya Kondadasula, Elyse Tomashewski, Patricia Steele, Melissa Giroux
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Metastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors
Externí odkaz:
https://doaj.org/article/57a46f642d4b4f41b29378a6a4fcd193
Autor:
Lawrence G. Lum, Archana Thakur, Minsig Choi, Abhinav Deol, Vidya Kondadasula, Dana Schalk, Kristie Fields, Melissa Dufrense, Philip Philip, Gregory Dyson, Hussein D. Aon, Anthony F. Shields
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3–8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs) to determine safety, the maximum tole
Externí odkaz:
https://doaj.org/article/37883bb3779b4c5ca386040a5d50fb03
Autor:
Melissa Giroux, Vidya Kondadasula, Archana Thakur, Dana L Schalk, Zaid S. Al-Kadhimi, Kristie Fields, Patricia A. Steele, Abhinav Deol, Elyse Tomashewski, Lawrence E. Flaherty, Lawrence G. Lum, Qin Liu, Michael S. Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMetastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors.
Autor:
Dana L Schalk, Melissa Dufrense, Vidya Kondadasula, Archana Thakur, Philip A. Philip, Minsig Choi, Abhinav Deol, Hussein D Aon, Anthony F. Shields, Lawrence G. Lum, Gregory Dyson, Kristie Fields
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3–8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs) to determine safety, the maximum tole
Autor:
Hemchandra Mahaseth, Greg Dyson, Lawrence G. Lum, Archana Thakur, Minsig Choi, Kristie Fields, Vidya Kondadasule, Abhinav Deol, Philip A. Philip, Dana Schalk, Anthony F. Shields, Elyse N. Tomaszewski
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Conventional chemotherapy for locally advanced pancreatic cancer (LAPC) and metastatic PC (MPC) is associated with clinical toxicities, dismal response, and poor survival rates. Novel approaches are needed. Preclinical studies show